61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

  • Pharma
  • July 11, 2025
  • 59 views
India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

July:  India’s Glenmark Pharmaceuticals (GLEN.NS), opens new tab said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie (ABBV.N), opens new tab have signed an exclusive licensing agreement…

  • Pharma
  • July 10, 2025
  • 136 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies